January 2020

Uncategorised

Informacije za ljekare

22 January 2020 /

Pseudomyxoma peritonei (PMP) je rjetko oboljenje sa incidencom od oko 3,2:1 000 000. To je dijagnoza koju ljekar može postaviti jednom do dva puta ili čak ili nijednom u toku čitavog radnog vijeka. Obično je teško napraviti diferencijaciju između PMP i drugih mnogo učestalijih tipova mucinoznih tumora, kao što je karcinom ovarija, bez temeljite patohistološke evaluacije iskusnog patologa. To je dijagnoza koju ljekar može postaviti jednom do dva puta ili čak nijednom u toku čitavog radnog vijeka. Obično je teško napraviti diferencijaciju između PMP i drugih, mnogo učestalijih tipova mucinoznih tumora, kao što je karcinom ovarija, bez temeljite patohistološke evaluacije iskusnog patologa. Pseudomyxoma je opsežno diseminirana mucinozna neoplazma koja se…

Read More
Events

COST Annual General Meeting and Pathology Workshop

4 January 2020 /

The annual Management Committee and Working Group meeting of the EuroPMP COST Action will take place on the 13th March 2020 in Basingstoke, U.K. A pathology workshop will be held the day before the AGM (12th March), looking into the most recent advances in the field of PMP pathology with speakers from around the world set to take the podium. A draft programme is available here. The meeting and the associated workshop will be held at the Ark Conference Centre, Basingstoke and North Hampshire Hospital, Basingstoke, U.K. The registration form may be accessed here.

Read More

Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin.(Read paper)
Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study.(Read paper)
Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study.(Read paper)
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin.(Read paper)
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification.(Read paper)
A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei.(Read paper)
Primary and secondary tumors of the peritoneum: key imaging features and differential diagnosis with surgical and pathological correlation.(Read paper)
Pseudomyxoma Peritonei Arising from Urachal Mucinous Neoplasms: a Case Series and Updated Literature Review.(Read paper)
Long-Term Survival in Patients Treated by Cytoreductive Surgery with or Without HIPEC for Peritoneal Surface Malignancies-A report from the Indian HIPEC Registry.(Read paper)
Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.(Read paper)